SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), initiation of coverage, Nov 19, 2026
SELLAS’s vaccine works, but its market is too small for a $3.9bn price
SELLAS is a 13-employee biotech whose leukaemia vaccine GPS just extended survival in a Phase 3 trial, and the shares jumped 156%. The market now prices more patients than the disease provides, and we see 54% downside.
- Our rating
- Sell
- 12-month target
- $8.77
- Price, Nov 17, 2026
- $19.15
- Expected return, with dividend
- −54%
By Penmark Team
What SELLAS is now
A 13-person company with no sales, betting on one leukaemia vaccine
SELLAS licenses blood-cancer drugs from others and runs their trials. Its lead drug, the vaccine GPS, extended median survival to 24.0 months from 14.7 months in its Phase 3 REGAL trial.
With no product sales, SELLAS pays for its trials by selling shares. Its share count rose from 15.5m in FY21 to 212.4m by the end of FY26E. Each new share sale dilutes existing holders.
Risk-adjusted net present value (rNPV) per share, before corporate costs, tax and net cash. Source: Penmark Research estimates.
Weighted average shares for FY21 to FY25; FY26E is the year-end count. Fiscal years end in December. Source: SEC filings, Penmark Research estimates.
What you are really buying
Even certain approval is worth $6.36 a share, a third of the price
Our base value is $4.97 a share. Removing all approval risk for GPS in second remission adds only $1.39, to $6.36, still 67% below $19.15. Approval risk is not the main gap.
The rest of the price, $12.79 a share, pays for sales the disease cannot supply. The price implies $4,923m of peak US GPS sales, 3.44 times our forecast. No plausible patient count supports that.
Certain approval means 100% approval odds for GPS in second remission (CR2), worth $6.36 a share. Source: Penmark Research estimates.
Where we disagree: how many patients
Only about 1,700 US patients a year qualify for GPS’s first use
About 21,000 US adults develop AML each year. Only 13.5% reach a second remission, and 60% of those cannot have a transplant, leaving 1,701 eligible patients. That is a small market.
At 45% peak share and $300k a year, US sales in this use top out at $418.5m before risk. Pricing at the market’s $400k adds only $1.95 a share. Price is not the swing factor.
AML is acute myeloid leukaemia. Peak share is 45% of eligible patients. Source: SELLAS presentation, Penmark Research estimates.
Where we disagree: approval odds
One small open-label trial leaves a real chance the FDA asks for more
REGAL enrolled 126 patients, was open-label and cut its target deaths from 105 to 80 in 2022. Its p-value of 0.035 came without confidence intervals. We treat that evidence with caution.
We give GPS a 65% chance of approval, against 85% or more in the market. Lifting our odds to 85% adds just $0.79 a share, to $5.77. Approval odds are not what makes the shares expensive.
Industry rate is the BIO 2011 to 2020 filing-to-approval base rate across all indications. Source: BIO, Informa, QLS, Penmark Research estimates.
Where we disagree: cash and new shares
Losses more than double next year, and more shares will be needed
Filing for approval, preparing a launch and starting a five-year trial in first remission lift FY27E costs to $110.2m. We expect a $101.0m loss, against $26m from analysts. Costs rise before any sales arrive.
Even after the planned $150m share sale, SELLAS needs a further $37m of equity in FY28E and FY29E. Diluted shares reach 230.9m. Each raise dilutes holders further.
Analysts’ forecast is a single consensus estimate. Fiscal years end in December. Source: SEC filings, Simply Wall St, Seeking Alpha, Penmark Research estimates.
The odds
Only our good case, at 20% odds, beats today’s price
We weight three cases: 30% bad, 50% middle and 20% good. The good case, $26.77, needs 85% approval odds, $450k pricing and 70% uptake. The bad case leaves almost nothing for shareholders.
The weighted value of $7.90 rolls forward to our $8.77 target. A Hold would need about a 55% weight on the good case, or a price below $9.74. Neither looks likely to us.
- Good, 20%85% approval odds, a $450k price, 70% uptake in second remission and 50% odds for first remission.
- Middle, 50%65% approval odds, a $300k price, 45% uptake and a FY28E launch.
- Bad, 30%A confirmatory study cuts approval odds to 40% and launch slips to FY29E.
Circle size shows how likely we think each case is. Case values are present values; the target weights all three and rolls forward 12 months at an 11.1% cost of equity. Source: Penmark Research.
What would change our mind
Full REGAL data and FDA feedback by mid-2027 will test our odds
Full survival curves and subgroups, then the FDA’s feedback before filing, decide whether our 65% approval odds are too low. These are the next data points investors will see.
We would turn more positive if the FDA accepts the filing without conditions, pricing reaches $450k and a partner funds the first-remission trial. Each of those would raise our value. Until then, we stay at Sell.
We assume $17.00 a share for the $150m offering.
SLS009 data and doctors’ and payers’ views on GPS pricing; we model $300k a year.
Results for patients who had venetoclax, and whether the FDA asks for a confirmatory trial.
We model $19.0m of risk-adjusted FY28E sales; analysts expect $122m.
Inside the full report
What each page covers after the summary on pages 1 and 2. Each opens the full report at that page.
See all 26 pages
- 3Modelled FY27E loss of $101.0m is 3.9x consensus as FY27E sales look unlikely
- 4SLS trades at 21.8x FY30E sales against a 2.3x commercial oncology peer median
- 5Current valuation implies 3.4x our peak US GPS sales forecast
- 6One-at-a-time market debate concessions sum to $5.43/sh above our $4.97 base
- 7Thirteen staff, zero product sales, and a $3.9bn valuation resting on 1,701 patients a year
- 8Two in-licensed drugs carry 5%–6% royalties and $110.2m of FY27E pre-launch burn
- 9GPS accounts for 93% of gross programme rNPV before $518.2m of overhead and tax
- 10Unfit second remission offers 1,701 US patients yearly against 7,718 in first remission
- 11REGAL gives GPS a 9.3-month survival lead in CR2, while CR1 faces oral incumbents
- 12Insiders hold 1.3%; share count rose from 15.5m (FY21A) to 212.4m (FY26E)
- 13Binary REGAL readouts explain 70% of return shocks while dilution absorbs 5-year gains
- 14Daily variance rests on binary GPS readouts while quarterly filings fail to move SLS
- 15Even 100% CR2 approval values SLS at $6.36 because only 1,701 US adults qualify
- 16One open-label 126-patient study leaves a 35% risk of FDA delay or rejection
- 17BLA filing, pre-launch build and a five-year CR1 trial lift FY27E spend to $110.2m
- 18Zero product sales keep GAAP losses aligned with external trial cash burn
- 19Risk-adjusted revenue starts at $19.0m in FY28E and reaches $563.3m in FY35E
- 20Pre-launch build lifts FY27E net loss to $101.0m vs $26.0m in stale consensus
- 21Sum-of-programmes rNPV values SELLAS at $4.97/sh base and $8.77/sh 12-month target
- 22Peer exit cross-check yields $4.11/sh (−17.4% vs rNPV), confirming overvaluation
- 23Probability-weighted scenarios roll forward to $8.77/sh (−54.2% return); zero tests flip Sell
- 24Upcoming REGAL subgroup data, FDA pre-BLA minutes and deal pricing test our $8.77 target
- 25M&A or elevated short interest pose upside risks to Sell; our bear case values SLS at $0.18
- 26Short interest reached 57.1m shares ahead of REGAL; 13F filers report 35.2% of shares
- 27Summary statements, programme rNPV & quarterly history from FY24A through FY35E
- 28Six-company peer set, glossary, methodology notes & primary data sources
Penmark Research. This summary draws on our initiation report on SELLAS Life Sciences Group, Inc., published Nov 19, 2026. It is not investment advice. Analyst certification, rating definitions and important disclosures are in the full report.